Ken Griffin Maxcyte, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.68 - $5.06 $1,472 - $2,023	400 Added 66.67%	1,000 $3,000
Q2 2024 Aug 14, 2024	SELL	$3.63 - $5.0 $6,534 - $9,000	-1,800 Reduced 75.0%	600 $2,000
Q1 2024 May 15, 2024	BUY	$3.94 - $5.38 $9,456 - $12,912	2,400 New	2,400 $10,000
Q3 2023 Nov 14, 2023	SELL	$3.02 - $5.1 $302 - $509	-100 Reduced 10.0%	900 $2,000
Q2 2023 Aug 14, 2023	SELL	$3.69 - $5.35 $7,011 - $10,165	-1,900 Reduced 65.52%	1,000 $4,000
Q1 2023 May 15, 2023	SELL	$4.03 - $5.89 $2,418 - $3,534	-600 Reduced 17.14%	2,900 $14,000
Q4 2022 Feb 14, 2023	SELL	$4.92 - $7.4 $43,788 - $65,860	-8,900 Reduced 71.77%	3,500 $19,000
Q3 2022 Nov 14, 2022	BUY	$4.52 - $6.51 $903 - $1,302	200 Added 1.64%	12,400 $81,000

124

65.6M

Ticker MXCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 101,724,000
Market Cap $348M
Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.